S.3 Ep. 6 | Beyond the Headlines
Streaming now on: Amazon Music | Apple Podcasts | Spotify | Soundcloud | YouTube
Learn More About Beyond the Endpoint | View All Episodes
In this special Beyond the Headlines episode, hosts Emily O'Brien, Manesh Patel, and Daniel Edmonston look past the press releases from the 2026 American Heart Association (AHA) Scientific Sessions in Chicago. They open with a behind-the-scenes look at Patel's view of the meeting as this year’s AHA volunteer president and the theme of his presidential lecture: science's last mile. The hosts then break down the implications of the ZEUS and Lp(a) HORIZON trials, where therapies lowered biomarker targets without reducing cardiovascular events. The hosts consider why well-designed randomized trials remain the only reliable path to answers about outcomes. Next, they turn to a few of the more than 60 sessions featuring DCRI faculty: the RACE-CARS cardiac arrest trial, the RECOVER-AUTONOMIC trial in long COVID, the Test 2 Treat implementation study on LDL cholesterol testing, and a VESALIUS-CV cost-effectiveness analysis of evolocumab. The hosts also share the dark horse presentations that caught their eye, from renewed debate over blood pressure targets in diabetes to agentic AI in health systems. They then consider how closing the last mile for delivery can become the first mile for discovery.
Related Headlines from this Episode
- DCRI Coverage of the AHA Scientific Sessions (DCRI)
- American Heart Association President Manesh Patel calls on cardiovascular community to solve science’s “last-mile problem” (Duke School of Medicine)
- New Data at AHA 2026 Demonstrates the Value of Treatment with Repatha® Earlier in the Cardiovascular Risk Continuum (Amgen)
- Community and EMS Interventions to Improve Survival in Cardiac Arrest (NEJM)
- Science News from AHA Scientific Sessions 2026 (AHA)
- American Heart Association Council on Quality of Care and Outcomes Research (American Heart Association)